|
[Related PubMed/MEDLINE]
Total Number of Papers: 123
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: TATI |
| Long Form |
: tumor-associated trypsin inhibitor |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2021 |
TATI, TAT-2, and CRP as Prognostic Factors in Colorectal Cancer. |
CI, CRP, TAT-2 |
| 2 |
2021 |
Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status. |
DSS, HPV, HUS, OS, S-TATIs |
| 3 |
2020 |
Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers. |
ERCC1, FGFR3, TP53 |
| 4 |
2020 |
Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma. |
CKD grade, CSS, RCC |
| 5 |
2020 |
Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer. |
CI, CRP, IQR, TAT-2 |
| 6 |
2019 |
Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy. |
OS, PFS |
| 7 |
2018 |
Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men. |
AA, ANX2, HSP60, PCa, SPINK1, TRUS, WHO |
| 8 |
2018 |
Postoperative CEA is a better prognostic marker than CA19-9, hCGbeta or TATI after resection of colorectal liver metastases. |
CA19-9, CEA, hCG-beta |
| 9 |
2016 |
Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI. |
CEA, ROC |
| 10 |
2015 |
Biomarker development, from bench to bedside. |
hCG, PSA, SPINK1, TAT |
| 11 |
2015 |
Claudin-5 is associated with elevated TATI and CA125 levels in mucinous ovarian borderline tumors. |
CA, TJ |
| 12 |
2015 |
Emerging Roles of SPINK1 in Cancer. |
PSTI, SPINK |
| 13 |
2015 |
Tumor-associated trypsin inhibitor in patients with endometrial cancer. |
--- |
| 14 |
2014 |
Assessment of the tumor-associated trypsin inhibitor (TATI) marker in patients with carcinoma of the uterine body 17 years after treatment. |
--- |
| 15 |
2014 |
Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma: potential implications for viral hepatocarcinogenesis. |
ESTs, HCC, HCV, MMPs, RT-PCR, SPINK1, TIMPs |
| 16 |
2014 |
TATI as a biomarker. |
PSTI |
| 17 |
2013 |
A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells. |
GS, PCa |
| 18 |
2013 |
A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diagnosis of metastasis in patients with breast cancer. |
sEGFR, TATI-MBCS |
| 19 |
2013 |
Pancreatic secretory trypsin inhibitor causes autocrine-mediated migration and invasion in bladder cancer and phosphorylates the EGF receptor, Akt2 and Akt3, and ERK1 and ERK2. |
PSTI |
| 20 |
2013 |
Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-beta (hCGbeta) in patients with hepatocellular carcinoma. |
HCC, hCG-beta, IFMA |
| 21 |
2013 |
The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer. |
ELISA |
| 22 |
2012 |
Creatinine clearance, cystatin C, beta2-microglobulin and TATI as markers of renal function in patients with proteinuria. |
B2M, CrCl, CYST, ESRD, GFR |
| 23 |
2012 |
Validation and comparison of tumor-associated trypsin inhibitor (TATI) immunoassays. |
RIA |
| 24 |
2011 |
Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder. |
UCB |
| 25 |
2011 |
Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients. |
OS, RT |
| 26 |
2011 |
Roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases. |
EGF, SPINK1 |
| 27 |
2010 |
Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. |
CRC, DFS, OS, s-TATI, t-TATI |
| 28 |
2009 |
High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. |
CEA, IHC, TMAs |
| 29 |
2008 |
Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells. |
CM-5M21 |
| 30 |
2008 |
Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer. |
AUC, CI, HR, pT, SPF |
| 31 |
2008 |
Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma. |
UBC |
| 32 |
2008 |
Urinary matrix metalloproteinase -8, -9, -14 and their regulators (TRY-1, TRY-2, TATI) in patients with diabetic nephropathy. |
DNP, MMP-9, PMN, TRY |
| 33 |
2007 |
Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. |
CgA, PSA |
| 34 |
2007 |
Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. |
ETR, HCC, PV |
| 35 |
2006 |
Effects of cigarette smoking on serum fluoride concentrations and renal function integrity after 1 MAC-h sevoflurane anaesthesia. |
--- |
| 36 |
2005 |
Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics. |
CEA, US |
| 37 |
2005 |
Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. |
--- |
| 38 |
2005 |
High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. |
--- |
| 39 |
2005 |
Preoperative serum hCGbeta as a prognostic marker in primary fallopian tube carcinoma. |
PFTC |
| 40 |
2005 |
Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. |
NMP22, ROC, TCC |
| 41 |
2004 |
Assessment of tumor-associated trypsin inhibitor (TATI) as a marker of renal function. |
Cr, GFR, LMW |
| 42 |
2004 |
Cyst fluid tumor-associated trypsin inhibitor may be helpful in the differentiation of cystic pancreatic lesions. |
CEA, CPN, EC, MCA, SCA |
| 43 |
2004 |
Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. |
--- |
| 44 |
2003 |
Co-expression of trypsin and tumour-associated trypsin inhibitor (TATI) in colorectal adenocarcinomas. |
RT-PCR |
| 45 |
2003 |
Fluoride metabolism in smokers and non-smokers following enflurane anaesthesia. |
CI, MAC |
| 46 |
2003 |
Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor. |
--- |
| 47 |
2003 |
Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. |
--- |
| 48 |
2003 |
Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. |
MSPs |
| 49 |
2003 |
Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies. |
CEA, CRP |
| 50 |
2002 |
MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells. |
MMPs, TAT-2 |
| 51 |
2002 |
Tumor-associated trypsin inhibitor. |
--- |
| 52 |
2001 |
Association of trypsin-2 with activation of gelatinase B and collagenase-2 in human bronchoalveolar lavage fluid in vivo. |
BALF, MMPs, PI |
| 53 |
2001 |
Preoperative serum concentration of hCGbeta as a prognostic factor in ovarian cancer. |
--- |
| 54 |
2001 |
Relationship between renal function and blood level of chromogranin A. |
CgA, GFR |
| 55 |
2001 |
Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer. |
TPA |
| 56 |
2001 |
The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. |
MMPs |
| 57 |
2001 |
Trypsinogen-1, -2 and tumour-associated trypsin-inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas. |
--- |
| 58 |
2000 |
Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. |
CMTs, DOXY, MMP |
| 59 |
2000 |
Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia. |
GFR, SCC, TPA, TPS |
| 60 |
1999 |
Elevated serum inhibin and tumor-associated trypsin inhibitor concentrations in a young woman with dysgerminoma of the ovary. |
--- |
| 61 |
1999 |
TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer. |
CA125 |
| 62 |
1999 |
Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. |
PSTI, RCC, RT-PCR |
| 63 |
1998 |
Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in Stage III epithelial ovarian cancer. |
--- |
| 64 |
1998 |
Serum levels of tumor associated trypsin inhibitor (TATI) and glomerular filtration rate. |
beta2m, GFR |
| 65 |
1998 |
Tumor-associated trypsin inhibitor (TATI) and renal function. |
GFR |
| 66 |
1997 |
Serum levels of the tumour-associated trypsin inhibitor in patients with endometriosis. |
--- |
| 67 |
1996 |
Serum tumour-associated trypsin inhibitor (TATI) and renal function. |
beta2m, GFR, MW |
| 68 |
1996 |
TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder. |
AFP, beta-hCG, CEA, PSA, SCC, TPA |
| 69 |
1995 |
Markers supplementing CA 125 in ovarian cancer. |
AFP |
| 70 |
1995 |
TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer. |
--- |
| 71 |
1995 |
Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer. |
CA125 |
| 72 |
1995 |
Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242. |
--- |
| 73 |
1995 |
Tumour-associated trypsin inhibitor and renal cell carcinoma. |
RCC |
| 74 |
1994 |
Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer. |
--- |
| 75 |
1994 |
Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma. |
CEA |
| 76 |
1993 |
Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids. |
CEA |
| 77 |
1993 |
Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. |
IFMA, RIA, SAB, SAB-IFMA |
| 78 |
1993 |
Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening. |
CEA, NSE |
| 79 |
1993 |
Squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), and tumour-associated trypsin inhibitor (TATI) for monitoring head and neck cancer. |
CEA, SCC |
| 80 |
1993 |
[Clinical evaluation of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological tumor]. |
--- |
| 81 |
1992 |
Chemotherapy as initial treatment for cervical carcinoma: clinical and tumor marker response. |
CEA, SCC |
| 82 |
1992 |
Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptide specific antigen in follow up of stage III cervical cancer. |
SCC, TPS |
| 83 |
1992 |
[Renal cell cancer in childhood]. |
--- |
| 84 |
1992 |
[Significance of the the tumor markers, Ca-125 and tumor-associated trypsin inhibitor in patients with carcinoma of the cervix and uterus]. |
--- |
| 85 |
1991 |
Biology and function of tumor-associated trypsin inhibitor, TATI. |
PSTI |
| 86 |
1991 |
Clinical evaluation of tumor-associated trypsin inhibitor (TATI). Proceedings of a symposium. Barcelona, September 24, 1989. |
--- |
| 87 |
1991 |
Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer. |
--- |
| 88 |
1991 |
Evaluation of TATI and other markers in solid tumors. |
--- |
| 89 |
1991 |
Evaluation of tumor-associated trypsin inhibitor (TATI) in women with benign and malignant gynecological disease. |
--- |
| 90 |
1991 |
Human colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor-associated trypsinogen. |
TAT-I |
| 91 |
1991 |
Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases. |
--- |
| 92 |
1991 |
Serum TATI levels and clinical correlation in tumors of the head and neck. |
ENT, RIA |
| 93 |
1991 |
Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease. |
--- |
| 94 |
1991 |
Tumor-associated trypsin inhibitor (TATI) in bone diseases. |
--- |
| 95 |
1991 |
Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA. |
CEA |
| 96 |
1991 |
Tumor-associated trypsin inhibitor (TATI) in pleural effusions. |
--- |
| 97 |
1991 |
Tumor-associated trypsin inhibitor (TATI) in primary esophageal carcinoma. |
--- |
| 98 |
1991 |
Tumor-associated trypsin inhibitor (TATI) in the diagnosis of lung cancer. |
--- |
| 99 |
1991 |
Tumor-associated trypsin inhibitor as a possible marker in male infertility. |
--- |
| 100 |
1991 |
Tumor-associated trypsin inhibitor in induced and acquired immunodeficiency. Studies on transplanted and HIV-infected patients. |
--- |
|
A Search Service for Abbreviation / Long Form
